Opens in a new tab

Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9060/2024, 20 February 2024)

Date20 February 2024
CourtCFI
DivisionParis (FR) Central Division - Seat
Type of actionGeneric application
Case number(s)UPC_CFI_454/2023
Registry referenceApp_8391/2024 · ORD_9060/2024 · UPC_CFI_454/2023
PartiesRoche Diabetes Care GmbH

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 20 February 2024 (UPC_CFI_454/2023), the judge-rapporteur of the Paris Central Division, in the revocation action against EP 2 196 231 brought by Tandem Diabetes Care, Inc. and Tandem Diabetes Care Europe B.V. against Roche Diabetes Care GmbH, rejected Roche’s request to extend the time limit for its Defence to revocation on the ground that a preliminary objection to jurisdiction was pending. The order confirms that extensions remain exceptional and that a preliminary objection does not, of itself, suspend the time limit for the Defence.

Question

Do a pending preliminary objection, the cost of possibly wasted pleadings and the risk of a stay of parallel proceedings justify extending the time limit for the Defence (Rule 9.3 RoP) or a decision otherwise under Rule 19.6 RoP?

Decision

The judge-rapporteur recalled that Rule 9 RoP confers a discretion to be exercised in line with proportionality, flexibility, fairness and equity (paragraphs 8 and 9), and that time limits serve speed, a fair trial and legal certainty (paragraphs 10 to 15). Extensions must be granted with caution and only in justified exceptional cases, the requesting party having to show that compliance is objectively impossible or very difficult (paragraphs 16 and 17). Roche alleged no such difficulty, only the risk of wasted pleadings should the objection succeed (paragraph 18), the risk of a stay of the non-infringement action was irrelevant (paragraph 19). Under Rule 19.6 RoP the time limit for the Defence runs despite the preliminary objection unless decided otherwise, which requires the same justification (paragraphs 20 to 23).

Key points for practice

Provisions applied

Rules of Procedure
Rules 9.3, 9.4, 19.6, 23, 48, 76.3 and 333
Case law cited
ITCiCo Spain, Paris Central Division, 9 February 2024, Paris Central Division, order of 10 November 2023, UPC_CFI_255/2023

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_454/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic application
Outcome (Dhenne Avocats summary)
Le juge rapporteur rejette la prorogation du délai de défense à l'action en nullité : l'exception préliminaire pendante ne suffit pas, faute de difficulté objective démontrée à respecter le délai.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 196 231
System for ambulatory drug infusion comprising a filling apparatus for flexible containers
recorded proprietor: F Hoffmann La Roche AG et Roche Diagnostics GmbH
Mentioned in the analysis (role not qualified)
Also mentioned in 9 other decision(s): Tandem Diabetes Care Europe v Roche Diabetes Care (CFI, 18 December 20 · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 3 July 2025) · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 5 June 2025) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 9 September 2024) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 26 July 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 27 June 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 10 May 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9062/2024, 20 Feb
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.